Clinical trial NCT00963495: Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Official title: Phase 1 Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Myelodysplasia
Lymphoma, Non-Hodgkin
Hodgkin's Lymphoma
Multiple Myeloma
Keywords: clioquinol
relapsed and refractory hematologic malignancy
ALL
HD
CLL
High risk myelodysplasia (MDS) with an IPSS score >2.5
CML blast crisis
Relapsed or refractory acute myeloid leukemia (AML)
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2009-08-21
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies. The study will also characterize Cliquinol's safety, tolerability and pharmacodynamic effect.

Detailed description: This is an open-label, single arm study. Approximately 4-48 patients will be enrolled. Patients will receive 800mg/day of Clioquinol at the start of the trial and the dose will be increased by 800mg with each subsequent level until the MTD is determined. Patients will then increase their frequency of the drug. Response to Clioquinol will be determined on day 21 for the 8 and 15 day dosing schedule and on day 28 for the 22 day dosing schedule ( 1 cycle). Patients who have demonstrated a response to the drug will be eligible to receive up to 5 additional cycles at the same dose and frequency every 21 days.

Eligibility criteria: Inclusion Criteria:

1. Relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), high risk myelodysplasia (MDS) with an IPSS score \> 2.5, Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HD) or multiple myeloma, for which all potentially curative or standard salvage therapy options have been exhausted.
2. ECOG performance status \< 2.
3. Biochemical values within the following range:

   * Serum creatinine \< 2x upper limit of normal.
   * Total bilirubin \< 2x upper limit of normal, AST and ALT \< 5x upper limit of normal.
   * Normal serum B12 level.
4. Ability to maintain adequate oral intake of medication.
5. Ability to understand and sign informed consent.
6. Toxicity from prior chemotherapy has resolved.

Exclusion Criteria:

1. Uncontrolled systemic infection.
2. Uncontrolled intracurrent illness.
3. Pregnant or breast feeding.
4. CNS disease.
5. Neurologic symptoms related to intracurrent illnesses or unexplained causes.
6. Psychiatric illness that would limit compliance with study.
7. Receiving other systemic chemotherapy, other than hydroxyurea to control circulating blast counts, within 10 days of study entry. Hydroxyurea is permitted, however the dose must be stable and unchanged in the 7 days prior to initiation with Clioquinol.
8. Prior therapy with Clioquinol.
9. Use of other investigational antileukemic therapy within two weeks of study entry.
10. Given the neurological side of Clioquinol in the Japanese population, this population, this trial will exclude patients who have a parent of Oriental or Japanese origin or who self-identify as Oriental or Japanese (Appendix 9.2).
11. Active ocular problems including visual migraines and glaucoma.
12. Use of oral or intravenous heavy metal supplements including copper, zinc, and nickel.

Primary outcomes:
measure: To evaluate the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended phase II dose. To partially characterize the pharmacokinetics of Clioquinol in plasma following single and multiple oral dosing.
timeFrame: Varies
Secondary outcomes:
measure: To determine the pharmacodynamic effects of Clioquinol on activity of the proteasome and relationship to the steady-state plasma concentrations of Cliquinol following multiple dosing, and to determine the response rate of Cliquinol.
timeFrame: Varies
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Princess Margaret Hospital
state: Ontario
Study officials:
affiliation: Princess Margaret Hospital, Canada
name: Mark Minden, MD
role: PRINCIPAL_INVESTIGATOR
References: